Navigation Links
New Report Defines Challenges for New Entrants in Key Rheumatology Markets

MedPredict's Rheumatology Thought Leader Panel Creates a 'Fantasy Formulary' For 2015

SCOTTSDALE, Ariz., April 7 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis, lupus, gout and psoriatic arthritis.

To develop this analysis, entitled "Thought Leader Insight & Analysis: Rheumatology," MedPredict conducted a thought exercise with four North American and four European rheumatologists. The purpose was to identify their "must have" branded and generic drugs for their real-world practices in the year 2015. This report outlines each panelist's "Fantasy Formulary," and the strengths, weaknesses and product news for each pharmacotherapy that is mentioned.

"It is essential that drug developers consider the entire rheumatology practice when establishing their strategies going forward," according to Dr. Jeffrey Berk, MedPredict's president and one of the report's authors. "One key insight from our research is that drugs which will be beneficial across multiple indications are going to have an easier time getting on formulary."

The report will answer the following questions:

  • What are these thought leaders' top ten choices for their rheumatology practice in 2015?
  • How do their choices differ by geography, and why?
  • How will the availability of biosimilars for substitution of first generation biologics impact the environment for new entrants?
  • What is the preferred anti-TNF drug, and why?
  • Where will new mechanistic approaches, such as Jak and Syk inhibitors, IL-17, anti-B-cell, and others fit in the rheumatologist's armamentarium?

Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen, Amgen/Wyeth, Biogen Idec, Bristol-Myers Squibb, Can-Fite, Centocor, Centocor/Schering-Plough, Chelsea, GlaxoSmithKline/Genmab, Human Genome Sciences, Incyte, J&J/Alza, Lilly, Medarex, Merck, Merck Serono/ZymoGenetics, Mitsubishi Tanabe, Neovacs, Nitec/SkyePharma, Novartis, Pozen/AstraZeneca, Rigel, Roche, Roche/Chugai, Roche/Genentech/Biogen Idec, Sanofi-Aventis, Savient, Takeda, UCB, Vertex, and Wyeth/Trubion.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pain in the ICU report suggests comprehensive approach
2. Photos: Report Shows Youth Health Educators Reach More Poor Teens with a Message of Living Healthy Lives!
3. Chronic Pain Sufferers Report Relief: DRJ Group Teams With Adult Foster Care Facilities to Evaluate Effectiveness of Stopain Topical Analgesic
4. Hazardous Health Plans: Consumer Reports Investigation Finds Serious Gaps in Individual Health Insurance Policies
5. Consumer Reports Survey: Hands-On Therapies Among Top-Rated Treatments for Back Pain
6. U.S. Adults Needlessly Vulnerable to Vaccine-Preventable Diseases, According to New Report
7. MGT Capital Investments, Inc. Reports Fiscal 2008 Financial Results and Provides an Update on Recent Developments
8. IDM Pharma Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qualification
9. Allscripts Reports Fiscal 2009 Third Quarter Results
10. J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members
11. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: